IVA Inventiva S.A.

MIXED Impact: 6/10 6-K
Horizon weeks Filed Jun 12, 2026 Processed 2d 12h ago SEC 0001104659-26-073545
Notable filing: 6-K

Price Chart

Loading chart...

Executive Summary

Inventiva closed a multi-step capital restructuring on June 12, 2026: repaying €62.2M in EIB loans, repurchasing ~2.97M EIB warrants for €50M, and issuing €75M in convertible/amortized bonds with BlackRock/Claret (net €71.3M). An amendment to the subscription agreement formalizes a market-cap-based minimum cash covenant test (€30M floor, disapplied above €2B market cap). This replaces expensive/onerous EIB debt with BlackRock/Claret financing but adds future dilution via convertible bonds and warrants.

Actionable Insight

The restructuring eliminates expensive EIB debt and residual warrant overhang but creates moderate near-term dilution via convertibles. Monitor the June 30 shareholder vote on new EIB warrants and NATiV3 trial readout (Tranche C trigger). The minimum cash covenant (€30M floor) and market-cap testing mechanism provide early warning on financial health — below €2B market cap for 7 days could limit financial flexibility. The overall capital structure clean-up with BlackRock/Claret is credit-positive but the dilution and trial-dependency warrant a cautious stance.

Key Facts

  • Repaid €62,204,436 in EIB loans (including accrued interest, EIB waived early prepayment fees)
  • Repurchased and cancelled all 2,266,023 EIB Tranche A Warrants and 700,000 Tranche B Warrants for €50M (eliminating ~22.7M shares of potential dilution from those warrants)
  • Issued €35M Tranche A Convertible Bonds (conversion price €5.2893, 40% premium to equity offering price) and €40M Tranche B Amortized Bonds, net proceeds €71,298,750
  • Issued 1,624,196 Tranche A/B Lenders' Warrants (exercise price €4.1559, 10% premium) and 661,709 Tranche C Lenders' Warrants
  • Remaining EIB Tranche B Warrants (~2.44M) to be surrendered for new EIB warrants subject to shareholder vote on June 30, 2026
  • Minimum cash covenant set at €30M, with structured monthly testing; covenant disapplies if market cap exceeds €2B for 15 consecutive days, reapplies below €2B for 7 days
  • Convertible bonds convert into ~6.6M new ordinary shares at current conversion price; warrants represent ~2.3M additional shares if fully exercised
  • Tranche C Amortized Bonds (up to €55M) contingent on NATiV3 trial success and further equity raise
  • Annual general meeting scheduled for June 30, 2026

Financial Impact

Total proceeds from equity offering ($120M) + debt issuance (€75M gross / €71.3M net) less €62.2M debt repayment and €50M warrant repurchase creates net cash inflow of roughly €50-60M after all transactions. Dilution: ~27.3M ADS from equity offering (settled June 5), plus up to ~8.9M shares from convertible bonds + warrants combined, representing ~30-40% potential dilution vs pre-offering share count.

dilutiondebtcash runwaymarket capitalizationshare count

Risk Factors

  • NATiV3 trial failure would block Tranche C Amortized Bonds (€55M potential), requiring additional capital
  • Potential dilution from conversion/exercise of ~8.9M shares if convertibles and warrants are exercised
  • Remaining EIB warrant replacement subject to shareholder approval — failure could leave residual warrant overhang
  • Minimum cash covenant of €30M could restrict cash usage if market cap dips below €2B
  • Company still pre-revenue with significant operating losses; cash runway depends on trial milestones

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-073545
Document: tm2617723d2_ex99-1.htm0001104659-26-073545
Document: tm2617723d2_6k.htm0001104659-26-073545
Document: 0001104659-26-073545-index-headers.html0001104659-26-073545
Document: 0001104659-26-073545-index.html0001104659-26-073545
Document: 0001104659-26-073545.txt0001104659-26-073545
2 reports for IVA
Performance horizon
Filters
Rows
Reports for IVA — sortable, filterable
Type Now
Jun 12, 2026
2d ago
6-K
MIXED ★ 6/10
$3.86 awaiting T+20awaiting T+20$3.85 (−0.26%)
Jun 12, 2026
2d ago
6-K
NEUTRAL ★ 3/10
$3.83 awaiting T+20awaiting T+20$3.85 (+0.52%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 4h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access